October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- FDA designates Class 1 recall for embolization devices
- AI reshapes healthcare leadership
- The Joint Commission launches UNIFY 2025 to advance patient safety, healthcare quality
- Insights into spinal vs general anesthesia: Which comes out on top for same-day outpatient surgery?
- US News & World Report releases results of second annual ‘Best ASCs’ ratings
- Hospitals make steady gains in patient safety amid persistent challenges
- Partnership promises to expand liver transplant access, improve organ viability
- Certified Nurses Day spotlights specialty expertise
- Advance of AI in nursing prompts safety, autonomy concerns
- Study: Miniature pacemakers for neonates, infants perform reliably for two years
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement